Mayo Clinic Zooms in on Nanobacteria
Thursday February 1, 11:15 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP - News) announces scientists at Mayo, working under a collaborative agreement with Nanobac Pharmaceuticals Inc., have published an article in the Journal of Investigative Medicine regarding successfully isolating nanoparticles from human kidney stones in cell cultures. The Mayo scientists also isolated proteins, RNA and DNA that appear to be associated with the nanoparticles or CNPs.
Entitled "Mayo Clinic Zooms In On Nanobacteria," the paper describes why the Mayo researchers say the findings could lead to solving the mystery of whether nanoparticles are viable living forms that can lead to disease - in this case, kidney stones. "We are looking at how kidney stones start as very small calcifications inside the kidney and then eventually grow into stones," said Mayo Clinic's John Lieske. "In the laboratory, we have isolated nanoparticles from kidney tissue and kidney stones, and have successfully propagated them in culture. This does not clearly confirm the role of nanoparticles in the formation of kidney stones, but it offers insight not otherwise known."
Intriguingly, the study cites evidence that the calcification process is not driven solely by physical chemistry, but instead is influenced by specific proteins and cellular responses. "There are at least two novel hypotheses here in terms of how stones might actually form. One: an infectious agent. If that was the case, that would point us in the direction of using different kinds of treatments specific to an infectious agent. Two: the idea that cells drive calcification. That would suggest other alternative therapies," added co-researcher Virginia Miller.
Dr. Maniscalco, co-chair of Nanobac, stated, "We believed that CNPs play a major role in one of the most pervasive medical conditions in existence: calcification of arteries and organs. This study conducted by one of the lead medical and research facilities in the United States, lends credence to our beliefs."
About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals, Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348 |
